Anavex Life Sciences Corp.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Anavex Life Sciences Corp. generated cash of -$30,812,000, which is less than the previous year. Cash used in financing activities reached the amount of $11,975,000 last year. Net change in cash is therefore -$18,837,000.
Cash Flow
| 2015 | -4.22M | 0 | 12.25M |
|---|---|---|---|
| 2016 | -9.23M | 0 | 3.13M |
| 2017 | -9.01M | 0 | 27.27M |
| 2018 | -12.58M | 0 | 8.07M |
| 2019 | -18.52M | 0 | 17.78M |
| 2020 | -21.28M | 0 | 28.35M |
| 2021 | -30.38M | 0 | 153.24M |
| 2022 | -24.23M | 0 | 21.28M |
| 2023 | -27.78M | 0 | 29.65M |
| 2024 | -30.81M | 0 | 11.97M |
AVXL Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 151.02M | 149.15M | 152.10M | 29.24M | 22.18M | 22.93M | 27.44M | 9.18M | 15.29M | 7.26M |
Operating activities | ||||||||||
Net income | -43.00M | -47.50M | -47.97M | -37.90M | -26.28M | -26.29M | -17.45M | -13.46M | -14.73M | -12.10M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.25K | 995 |
Stock-based compensation expense | 9.43M | 16.37M | 18.37M | 8.23M | 4.87M | 6.43M | 5.51M | 4.13M | 5.06M | 1.63M |
| Deferred income tax benefit | 9.43M | 16.37M | 18.37M | 8.23M | 4.87M | 6.43M | 5.51M | 4.13M | 5.06M | 1.63M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 484K | 5.94M | -4.28M | -2.20M | -772.38K | 0 | 54.43K | 0 | 0 |
Inventories | 0 | 0 | -5.94M | 4.28M | 2.20M | 772.38K | 0 | 0 | 0 | 0 |
Accounts payable | 5.30M | 497K | -915.00K | 750.72K | 465.72K | 683.79K | 0 | 554.70K | -151.40M | 0 |
Cash generated by operating activities | -30.81M | -27.78M | -24.23M | -30.38M | -21.28M | -18.52M | -12.58M | -9.01M | -9.23M | -4.22M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Financing activities | ||||||||||
Common Stock Issued | 11.28M | 27.87M | 20.98M | 153.21M | 28.75M | 17.83M | 8.17M | 27.27M | 3.16M | 12.34M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -34.75K | 0 |
Cash used in financing activities | 11.97M | 29.65M | 21.28M | 153.24M | 28.35M | 17.78M | 8.07M | 27.27M | 3.13M | 12.25M |
Net Change In Cash | -18.83M | 1.86M | -2.94M | 122.85M | 7.06M | -745.00K | -4.50M | 18.25M | -6.10M | 8.02M |
Cash at end of period | 132.18M | 151.02M | 149.15M | 152.10M | 29.24M | 22.18M | 22.93M | 27.44M | 9.18M | 15.29M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |